Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Mifobate
Cat. No.:
0225LY-0819
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Mifobate is a specific and potent PPAR-gamma antagonist that demonstrates antiatherosclerotic, antidiabetic, and antiobesity properties.
Synonym:
76541-72-5; Clenicor; (4-Chlorophenyl)(dimethoxyphosphinyl)methyl phosphoric acid dimethyl ester; Phosphoric acid, (4-chlorophenyl)(dimethoxyphosphinyl)methyl dimethyl ester; CHEMBL284768; DTXSID6045741; NCGC00092299-01; (4-chlorophenyl)(dimethoxyphosphoryl)methyl dimethyl phosphate
CAS No.:
76541-72-5
Compound CID:
60910
Formula:
C11H17ClO7P2
Formula Weight:
358.65
Specification
Targets&IC50:
PPARγ: 140 μM (IC50)
Relative Density:
1.355 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Mifobate can be used in metabolic research to explore the regulation of lipid profiles and potential anti-atherosclerotic effects.
Library Information
Target:
PPAR
Receptor:
PPARγ
Pathways:
Metabolism; DNA damage/DNA repair
Plate Number:
AOCL-11
Plate Location:
e8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM Water
Water Max Solubility:
35.87 mg/mL; 100.01 mM
